Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug
Biogen made a surprise reversal on its Alzheimer's treatment drug with plans to now seek regulatory approval. Biogen CEO Michel Vounatsos joins CNBC's "Squawk Box" team to discuss the change.
Видео Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug канала CNBC Television
Видео Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Mukherjee: The projected energy demand is huge... it's going to double in the next few yearsCiti's Drew Pettit on opportunities in nuclear energyBreaking down shares of Hilton, Expedia and Match Group3-Stock Lunch: Ford, KB Home, & DoorDashBipartisan bill aims to let small businesses hedge commodity costs: Senators Shaheen and CassidyNielsen names NBCU top media distributor in AugustThree-Stock Lunch: S&P Homebuilders Index, Nvidia & JPMorganFinal Trades: Trane Tech, American Tower, Regeneron and Taiwan SemiTrade Tracker: Karen Firestone trims Adobe and buys more AutodeskEarnings trajectory is under-appreciated in the near-term, says HSBC's Max KettnerCalls of the Day: Starbucks, Uber, Lowe's, Walmart, Casey's General Store, AT&T and Charles SchwabMicron stock could continue to move higher, says BD8's Doran after Micron spikes on earningsSouthwest Airlines raises summer revenue forecast, authorizes $2.5 billion in share buybacksTrade Tracker: Bill Baruch trims Tesla, sells SLB and buys more Exxon Mobil and Kinder MorganTrade Tracker: Steve Weiss sells Archer-DanielAsam: I'm not aware of any criminal investigations into SAP at present, We're cooperating with DOJSeptember consumer confidence falls the most in three yearsFinal Trades: PayPal, Citizens Financial, Cisco Systems and the IYRYour Best Option: Micron earningsVistra overtakes Nvidia as S&P 500's top gainer in 2024Opening Bell, December 15, 2022